| abstract |
Disclosed in the present invention is a drug Ramipril (Altace) targeting an SOAT1 protein. Experiments show that the drug is the same as a positive control drug nevanimibe, and can be combined with SOAT1 so as to inhibit cholesterol from being converted into cholesteryl ester and increase the intracellular cholesterol level. Furthermore, cell proliferation experiments are performed on three cells of liver cancer cell lines HepG2, Hep3B, and Huh7 by means of the drug, it is found that the drug can obviously inhibit growth of liver cancer cells, and an IC50 value superior to that of a positive drug Avasimibe is obtained. Furthermore, animal in-vivo efficacy evaluation shows that Ramipril can significantly inhibit tumor growth of a mice in a PDX model of a liver cancer patient having high expression of SOAT1. The present invention provides a novel liver cancer treatment targeting drug from the perspective of the effect of the targeting SOAT1 protein on cholesterol homeostasis, and provides a new direction for clinical treatment of liver cancer. |